Secunderabad Chronicle

Trastuzumab Biosimilar Landscape Report 2023 by DelveInsight

 Breaking News
  • No posts were found

Trastuzumab Biosimilar Landscape Report 2023 by DelveInsight

May 04
20:36 2023
Trastuzumab Biosimilar Landscape Report 2023 by DelveInsight
Trastuzumab Biosimilar Landscape Report 2023 by DelveInsight
DelveInsight’s, “Trastuzumab Biosimilar Insight, 2023” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

DelveInsight launched a new report on Trastuzumab Biosimilar Insights 2023.

DelveInsight’s, “Trastuzumab Biosimilar Insight, 2023” report provides comprehensive insights about 35+ companies and 35+ marketed and pipeline drugs in Trastuzumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer. It is specifically used for cancer that is HER2 receptor positive. It may be used by itself or together with other chemotherapy medication. Trastuzumab is a humanized IgG1 kappa monoclonal antibody that selectively binds with high affinity to the extracellular domain of the human epidermal growth factor receptor 2 protein, HER2. Trastuzumab is produced by recombinant DNA technology in a mammalian cell (Chinese Hamster Ovary) culture which may contain the antibiotic gentamicin. Gentamicin is not detectable in the final product. Herceptin (trastuzumab) for injection is a sterile, white to pale yellow, preservative-free lyophilized powder with a cake-like appearance, for intravenous administration.

Click here and get access to free sample pages of the report

Trastuzumab Biosimilars Marketed Drugs

  • Kanjinti: Amgen
  • Herzuma: Celltrion

Trastuzumab Emerging drugs:

  • EG12014: EirGenix
  • HD201: Prestige BioPharma

Request for a detailed sample copy of the report: https://www.delveinsight.com/sample-request/trastuzumab-biosimilars-insight

Table of contents:

1. Key Insights

2. Trastuzumab Biosimilars: Snapshot

3. Executive Summary

4. Regulatory Outlook For Biosimilars

5. Trastuzumab (Reference Product: Herceptin)

6. Research and Development

7. Herceptin Biosimilar: Emerging Opportunities

8. Trastuzumab: Biosimilars Assessment

9. Trastuzumab Biosimilars Profiles: By Company

10. Trastuzumab Biosimilars: Comparative Landscape: By Company

11. Trastuzumab Biosimilars: Competitive Landscape

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Appendix 

16. Bibliography

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Download our full report: https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles

Recent Posts

Pioneering the Fight against Non-Small Cell Lung Cancer Pipeline: A Comprehensive Pipeline Review | Companies – BridgeBio Pharma, Daiichi Sankyo, Merck, Abbvie, Pfizer, Eli Lilly and Others

Read Full Article